ArticleThe Journal of general physiology2025
GSK3β-driven phosphorylation of ABLIM1 regulates its interactions with titin cardiac muscle.
Article in The Journal of general physiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
The heart adapts to cardiac demand via chemical modifications of contractile myofilament proteins. Many of these modifications, such as phosphorylation, occur in proteins' intrinsically disordered regions (IDRs). These IDRs, though challenging to study, are recognized as dynamic, tunable regulators of protein function. Since cardiac dysfunction often involves altered posttranslational modifications (PTMs) in myofilament proteins, understanding how IDR changes affect protein and myofilament behavior is crucial. We hypothesized that PTMs, primarily phosphorylation, regulate ABLIM1 (a myofilament protein) by altering its IDR conformational ensemble, thereby modulating its binding to other myofilament proteins. We tested this using multiscale modeling (including molecular dynamics simulations) to predict ABLIM1's conformational ensembles pre- and postphosphorylation at sites altered in a canine model of heart failure with reduced GSK3β activity. A state-based contraction model then rationalized the physiological consequences. Our data show that local physicochemical alterations from phosphorylation in ABLIM1's IDRs significantly affect its conformational ensemble. This ensemble change subsequently influences the ability of its LIM domains to interact with titin. Furthermore, using the contraction model, we show that a reduced ability to recruit myosin heads for cross-bridge formation, resulting from the modified LIM domain/titin interactions, provides a mechanism that elucidates previous findings of diminished length-dependent activation. These findings offer critical molecular insights, reframing IDRs not merely as structural noise but as key, tunable elements that control protein interactions and ultimately impact mechanical behavior in the sarcomere. This work bridges molecular disorder and biomechanical function, providing a new perspective to understand dynamic control and dysfunction in cardiomyocyte contraction.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.